about us

Vision

Be the first cool biologics tools company.

Path

Create big value through great products that let scientists do big things.

People

The right group of people can accomplish anything.

"Freedom lies in being bold."

- Robert Frost

Products

Events

CONFERENCES

PEGS China

Apr 5-7, Shanghai, China. Booth 13. Register.

PEGS Boston

Apr 25-29, Boston, MA. Booth 332. Register.

AAPS

May 16-18, Boston, MA. Booth 528. Register.

SEMINARS

BioPharm International Webinar: Way More Biologic Stability, a Lot Less Protein

Dec 10, 2015 Watch Recording.

GEN Webinar: Quantifying Stability and Determining Aggregation Pathways for Biologics

Oct 20, 2015 Watch Recording.

CHI Webinar: Predict the Future of Your Protein Stability

Jun 26, 2015 Watch Recording.

News

Feb 12, 2015

Unchained Labs has a busy first day! Raises $25 million and closes first acquisition. Read more.

Unchained Labs has a busy first day! Raises $25 million and closes first acquisition.

Pleasanton, CA February 12, 2015 – Start-up life sciences tools company Unchained Labs burst onto the scientific scene today, announcing a $25 million Series A Financing and the acquisition of Optim, the world’s first and only multiplex protein stability platform for biologics. The financing was led by Novo Ventures, Canaan Partners and TPG Biotech.

Unchained Labs is committed to building the next cool life science tools company. One that matters. One without old school rules. One with products that’ll make a real difference in the research scientists do every day.

The first Unchained product, Optim, lets scientists unlock optimal biologic formulations simply and quickly. For the first time, researchers can measure multiple protein stability parameters – including denaturing temperature and aggregation onset temperature – on multiple samples simultaneously. Assays are high throughput, label-free, ultra-low volume and very easy to run.

Over 60 Optim platforms have been sold to biopharma and academic customers worldwide. Unchained Labs purchased the Optim technology from The Avacta Group. The start-up plans to continue to buy businesses and product lines and add their magic touch for developing breakthrough products and selling them like crazy.

“We had a great experience with Tim in the life science tools space in the past and we believe there is a real opportunity to build another substantial company together,” said Jack Nielsen from Novo Ventures. “Combining organic and inorganic growth has proven to be a powerful strategy for creating value in this space and we can’t wait to see Unchained Labs grow.”

“I love what I do and I am completely pumped about building another great tools company,” said Tim Harkness, Founder and CEO of Unchained Labs. “For me this is all about people. The right group of people can accomplish anything, and we are starting out with fantastic investors and employees who are committed to creating something special together. Optim is a one-of-a-kind product that will provide a solid foundation for us.”

About Unchained Labs

Unchained Labs is committed to building the next cool life science tools company. One that matters. One without old school rules. One with products that’ll make a real difference in the research scientists do every day. We plan to buy businesses and product lines and then add our magic touch for developing breakthrough products and selling them like crazy. Our first product, Optim, is the world’s first and only multiplex protein stability platform for biologics. We are located in Pleasanton, CA and can be found online at www.unchainedlabs.com.

Contact:

Tim Harkness
Founder and CEO, Unchained Labs
tim.harkness@unchainedlabs.com

Download PDF of press release.

Feb 23, 2015

Unchained Labs UNleashes its newest leadership team members. Read more.

Unchained Labs UNleashes its newest leadership team members.

February 23, 2015 – Pleasanton, CA – Unchained Labs, a new life science tools company, introduced the latest members of its leadership team today. Each is a veteran in the life sciences arena and come to the start-up with solid backgrounds in building booming businesses from the ground-up. Their mantra? Create big value through great products that let scientists do big things.

The new crew includes Will Lachnit, Ph.D., VP Corporate Development, who’s been around the Life Sciences block a few times with 25 years-worth of leadership roles from Pharmaceutical R&D to Global Sales. Rick Gordon, VP Sales, is all about selling great scientific tools and has led sales teams in start-up, emerging growth, and market-leading tools and technology companies for 10 years. Taegen Clary, Sr. Dir. Marketing, can’t get enough when it comes to marketing cool lab gear and brings 8 years of team leadership and deep pharma and biotech market knowledge to the table. Krista Witte, Ph.D., Sr. Dir. Science, loves building assays and analytical tools to do great science, and her many titles span the gamut from Founding Member to Head of R&D over the past 15 years.

“I’ve said it many times, but the right group of people really can do anything. Hands-down, this is that group,” said Tim Harkness, Founder and CEO of Unchained Labs. “I’m also happy to say all of the core Optim team members are taking the plunge with us. The whole team is focused on making sure everything around this transition goes smoothly for current Optim customers, and everyone’s stoked about building this thing together.”

About Unchained Labs

Unchained Labs is committed to building the next cool life science tools company. One that matters. One without old school rules. One with products that’ll make a real difference in the research scientists do every day. We plan to buy businesses and product lines and then add our magic touch for developing breakthrough products and selling them like crazy. Our first product, Optim, is the world’s first and only multiplex protein stability platform for biologics. We are located in Pleasanton, CA and can be found online at www.unchainedlabs.com.

Contact:

Taegen Clary
Sr. Director of Marketing, Unchained Labs
taegen.clary@unchainedlabs.com

Download PDF of press release.

May 4, 2015

Unchained Labs lets the UNit loose. Read more.

Unchained Labs lets the UNit loose.

May 4, 2015 – Pleasanton, CA – Unchained Labs, a refreshingly new biologic tools company, extends its coming out to this year’s PEGS conference and launches the UNit — the first and only multiplex protein stability system for biologics. PEGS: The Essential Protein Engineering Summit takes place in Boston, May 4-8, 2015.

The UNit lets drug discovery researchers look at more protein stability parameters than any other tool out there. Its 7 applications, 144 sample a day throughput and 9 µL sample size ups their knowledge base on every formulation, gets them to the right candidates exponentially faster, and uses way less sample than existing techniques. They can make better decisions, make them earlier, and skip the wasted time and effort that goes into developing candidates with no potential.

“Protein unfolding and aggregation temperatures are the first two things formulation scientists need to get a handle on. With the UNit, they can screen both at the same time, and get their hands on data from 48 samples in 2 hours,” said Tim Harkness, Founder and CEO of Unchained Labs. “There isn’t another tool that can give scientists that much actionable information on protein stability that fast.”

The UNi consumable makes it all happen. It’s why the UNit can measure fluorescence and light scattering — techniques everybody’s got down — at the same time, label-free. To kick out unfolding and aggregation temp data for 144 samples a day with other techniques, researchers would quite literally need 30 competitive systems running in the lab at the same time. The UNit also lets them grab data on chemical denaturation, thermal recovery, isothermal stability, viscosity and membrane protein stability.

About Unchained Labs

Unchained Labs is committed to building the first cool biologic tools company. One that matters. One without old school rules. One with products that’ll make a real difference in the research scientists do every day. We plan to buy businesses and product lines and then add our magic touch for developing breakthrough products and selling them like crazy. Our first product, the UNit, is the world’s first and only multiplex protein stability platform for biologics. We are located in Pleasanton, CA and can be found online at www.unchainedlabs.com.

Contact:

Taegen Clary
Sr. Director of Marketing, Unchained Labs
taegen.clary@unchainedlabs.com
925.587.9806

Download PDF of press release.

Jun 4, 2015

Unchained Labs lands another win in the biologics stability market! Acquires AVIA Biosystems. Read more.

Unchained Labs lands another win in the biologics stability market! Acquires AVIA Biosystems.

June 4, 2015 ‐ Pleasanton, CA ‐ Unchained Labs upped its game in the biologics stability market today, announcing the acquisition of AVIA Biosystems, the developer of the Isothermal Chemical Denaturation (ICD) system for measuring biologic stability. This is the second acquisition for Unchained Labs this year.

The ICD system makes something that wasn’t possible before — the routine measurement of protein stability under denaturing conditions — totally doable. It completely automates the complex sample prep and data analysis needed to make these measurements, giving formulation scientists a true walk‐away solution. The ICD system is also a perfect complement for Unchained Labs’ first product, the UNit, which simultaneously measures the top two biologic stability indicators, protein unfolding and aggregation temperatures.

“We are totally committed to improving biologics characterization tools and the ICD is a great new tool that can actually help predict future drug stability,” said Tim Harkness, Founder and CEO of Unchained Labs. “The ICD and the UNit are a perfect pairing and really help establish us as the experts in protein stability. We have done a lot and done it quickly at Unchained Labs, but we are unwavering in our pledge to acquire any product or business that can make a real difference for biologics researchers.”

“I’m really looking forward to joining forces with the Unchained Labs team,” said Dr. Rick Brown, Co‐founder and President of AVIA Biosystems. “Together, our products will give drug discovery researchers the power to characterize and understand their biologics better than they ever could before.”

Unchained also announced the addition of $6 million to its Series A Financing, bringing the total Series A round to $31M. The original syndicate partners, Novo Ventures, Canaan Partners and TPG Biotech all participated in the financing.

About Unchained Labs

Unchained Labs is committed to building the next cool life science tools company. One that matters. One without old school rules. One with products that’ll make a real difference in the research scientists do every day. We plan to buy businesses and product lines and then add our magic touch for developing breakthrough products and selling them like crazy. We are located in Pleasanton, CA and can be found online at www.unchainedlabs.com.

Contact:

Taegen Clary
Sr. Director of Marketing, Unchained Labs
taegen.clary@unchainedlabs.com
925.587.9806

Download PDF of press release.

Jun 16, 2015

The new HUNK from Unchained Labs is turning heads! Read more.

The new HUNK from Unchained Labs is turning heads!

June 16, 2015 – Pleasanton, CA – Unchained Labs, a refreshingly new biologics tools company, UNleashed the HUNK today, the world’s first quantitative biologics stability predictor. The HUNK gives drug discovery scientists up-front insight on the stability of their protein formulations with information on how and if the safety and efficacy of their biologic will be affected during storage.

In a nutshell, the HUNK measures a time-tested thermodynamic value, ΔG, using chemical denaturation. This lets researchers determine if their protein will stay stable or aggregate over time. The kicker? The HUNK also tells them if their protein aggregates from the native or denatured state — something that can’t be done with any other tool today. Knowing which type of aggregation is the culprit gives scientists an immediate understanding of which corrective action to take. The HUNK also automates the complex sample prep and analysis process, making these once complicated and time-intensive measurements completely routine.

“The HUNK takes our biologics stability tools line up to the next level,” said Taegen Clary, Sr. Director of Marketing at Unchained Labs. “It UNlocks completely new and quantitative information about how proteins aggregate, and lets scientists visualize future stability in an entirely new way.”

About Unchained Labs

Unchained Labs is committed to building the first cool biologics tools company. One that matters. One without old school rules. One with products that’ll make a real difference in the research scientists do every day. We plan to buy businesses and product lines and then add our magic touch for developing breakthrough products and selling them like crazy. We are located in Pleasanton, CA and can be found online at www.unchainedlabs.com.

Contact:

Taegen Clary
Sr. Director of Marketing, Unchained Labs
taegen.clary@unchainedlabs.com
925.587.9806

Download PDF of press release.

Jul 9, 2015

Unchained Labs just can’t get enough, acquires Avid Nano, rocks out the new pUNk! Read more.

Unchained Labs just can’t get enough, acquires Avid Nano, rocks out the new pUNk!

July 9, 2015 – Pleasanton, CA – Unchained Labs just can’t get enough biologics stability tools, today announcing its acquisition of Avid Nano. Avid Nano designs, develops and manufactures highly sensitive dynamic light scattering (DLS) systems.

Also today, Unchained Labs UNcaged the pUNk, the world’s smallest, fastest and easiest to use protein sizing system. The pUNk is a high-performance DLS system that measures a protein’s hydrodynamic size, size distribution, aggregation population and molecular weight. Its speed and ease of use is all made possible by the low-cost BladeCell consumable, which is single use and only requires 5 µL of sample. The pUNk’s killer sensitivity comes from a proprietary optical design and distinct use of algorithms.

The Unchained Labs biologics stability tools line-up is quickly becoming one of the most enabling portfolios out there. First they nabbed the UNit, the only system that can simultaneously measure melting and aggregation onset temperatures. Next they captured the HUNK, the first fully automated platform that can predict if and how aggregation will occur. Today they snagged the pUNk, a highly sensitive tool for measuring protein size and aggregation.

“Wow! We have now acquired 3 product lines in 3 acquisitions in less than 5 months and we aren’t even close to done,” said Tim Harkness, CEO and Founder of Unchained Labs. “With this unique portfolio of tools we believe we can truly help researchers UNlock biologics stability.”

“I really look forward to joining the Unchained team,” said Ken Cunningham, Founder and CEO of Avid Nano. “DLS fits perfectly in the Unchained Labs portfolio and I am optimistic about where we can take the technology next.”

About Unchained Labs

Unchained Labs is committed to building the first cool biologics tools company. One that matters. One without old school rules. One with products that’ll make a real difference in the research scientists do every day. We plan to buy businesses and product lines and then add our magic touch for developing breakthrough products and selling them like crazy. We are located in Pleasanton, CA and can be found online at www.unchainedlabs.com.

Contact:

Taegen Clary
Sr. Director of Marketing, Unchained Labs
taegen.clary@unchainedlabs.com
925.587.9806

Download PDF of press release.

Our Team

READ BIO

Tim Harkness

Founder and CEO
Tim Harkness, Founder and CEO

Building great teams and great life sciences companies is just in Tim’s DNA. He has 2 successful exits under his belt and brings 20+ years of life science leadership experience to the Unchained Labs table. As CEO of ProteinSimple, Tim and team built a unique protein analysis pure-play from scratch. In 6 years, they grew revenue from $0 to $60M, raised over $60M of venture funding, completed 4 acquisitions and sold it for $300M. Prior to ProteinSimple, Tim spent 9 years as CFO at Molecular Devices where he helped drive revenue from $38M to $185M through internal growth and acquisitions before selling it for over $600M. In his early career as a healthcare investment banker, Tim helped raise over $1B for life science companies in the public equity markets. He’s currently Chairman of the Analytical, Life Sciences and Diagnostic Tools Association (ALDA), and has an M.B.A. from Stanford and a B.B.A from the University of Wisconsin. Tim is married with 3 children, is out hacking around on the links or riding his bike whenever he can, and happily gets up at the crack of dawn to coach his son’s hockey, lacrosse and baseball teams.

READ BIO

Jason Novi

CFO and COO
Jason Novi, CFO and COO

Jason wears a bunch of hats and loves to build businesses. He leads the finance, manufacturing, service and administrative functions for Unchained Labs, and is on the front line of fundraising, acquisitions and integrations. Prior to joining Unchained Labs, Jason was the CFO and VP of Operations at ProteinSimple, a part of Tim’s team that raised $60M, acquired four businesses and built a $60M+, profitable life sciences tools company over a six year period. That business was sold to Bio-Techne in July 2014 for $300M. Prior to joining ProteinSimple, Jason was VP of Finance at Nektar Therapeutics. Earlier in his career, he spent nearly seven years in various senior financial leadership roles at Molecular Devices, responsible for the worldwide accounting, finance and treasury functions, and Jason played a key role in the execution and integration of its corporate development activities. He began his career with Ernst & Young, based in San Francisco, California, holds a B.S. in Business Administration from Cal Poly San Luis Obispo, and is a CPA (inactive). Jason and his wife Erin have two kids, and when he isn’t coaching their softball and baseball teams, you can find him hacking away on the golf course or cheering on the SF Giants and 49ers.

READ BIO

Terry Salyer

CCO
Terry Salyer, CCO

Terry is all about helping customers up the pace of their research through better tools, and has sold thousands of life science systems in her 20-year career. Terry leads Global Commercial Operations at Unchained Labs, supporting customers with her field sales and applications teams. Prior to Unchained Labs, Terry was CCO at BioNano Genomics and VP of Sales at ProteinSimple, Pall ForteBio and Eksigent. She helped develop and sell products at each, and was integral in demonstrating the scientific impact of these new technologies to customers. Terry has a B.S. in Biotechnology from Minnesota State at Mankato. She spends her free time cooking and golfing, and jumps at the chance to travel to a great beach location any time she can. Terry is a huge fan of the Minnesota Vikings and plans on watching them take a Super Bowl someday.

READ BIO

Will Lachnit

VP Corporate Dev
Will Lachnit, VP Corporate Dev

Will’s been around the Life Sciences block a time or two, and can’t get enough when it comes to making companies thrive. He has over 25 years of experience in the life sciences industry across multiple functions. Prior to joining Unchained Labs, Will was the Senior Vice President of Global Sales and Solutions Development at Freeslate. Prior to Freeslate, he was the Vice President of Sales and Service for ProteinSimple. While there, his other roles included leadership of the marketing and applications functions and he played a key role in integrating 4 acquisitions. Previously, at Molecular Devices Corporation, Will had leadership roles for the North American Drug Discovery sales organization, an entrepreneurial product development organization in Switzerland, and Corporate Development. Dr. Lachnit started his career in Pharmaceutical R&D in scientific and research management positions at Roche and Syntex, including running a best-in-class HTS organization. He received his M.S. and Ph.D. in Pharmacology and his B.S. in Physiology from the University of California, Davis. Will has a passion for cooking for his family and loves tinkering around in his woodshop.

READ BIO

Krista Witte

VP Product Dev
Krista Witte, VP Product Dev

Krista loves building assays and analytical tools to do great science. She has over 15 years of experience in life sciences instrumentation and application development. Prior to joining Unchained Labs, Krista was a founding team member of ForteBio, now Pall ForteBio. In her decade at the company, she held many roles including heading up Applications, Assay Development, System Integration, QC and R&D. She saw the company from angel-funded start-up to a leading provider of label-free instrumentation. Prior to ForteBio, Krista headed up the Applications team at Zyomyx, taking a lead role in developing their protein microarray technology. Krista holds a Ph.D. in Carbohydrate Chemistry from The Scripps Research Institute and a B.S. in Chemistry from Texas A&M (Gig ‘em Aggies!). When not doing science, Krista is obsessed with being around the water and can be found swimming, diving or sailing.

READ BIO

Taegen Clary

VP Marketing
Taegen Clary, VP Marketing

Taegen loves marketing life science tools. He has over 15 years of experience using and marketing enabling life science instrumentation and consumables. As the Director of Pharmaceutical Segment Marketing at Agilent Technologies, he led the marketing organization focused on the company’s largest customer segment, which has experienced consistent, above-market growth rates and 2014 sales revenues of $1B. Over his 7 years at Agilent, Taegen was the Product Manager for Proteomics and Protein Chemistries and also led the Life Science group’s efforts in the area of protein therapeutics. He began his career at Berlex Biosciences, now a part of Bayer Healthcare, running mass spectrometers and developing assays to measure drug passage across the blood brain barrier. Taegen has an M.B.A. in Marketing from St. Mary’s College of California and a B.S. in Biotechnology from the University of California, Davis. Taegen is married with two children, loves mountain biking, camping, fishing, golfing and is huge fan of the San Francisco Giants and 49ers.

Board

READ BIO

Tim Harkness

Founder and CEO, Unchained Labs
Tim Harkness, Founder and CEO, Unchained Labs

Building great teams and great life sciences companies is just in Tim’s DNA. He has 2 successful exits under his belt and brings 20+ years of life science leadership experience to the Unchained Labs table. As CEO of ProteinSimple, Tim and team built a unique protein analysis pure-play from scratch. In 6 years, they grew revenue from $0 to $60M, raised over $60M of venture funding, completed 4 acquisitions and sold it for $300M. Prior to ProteinSimple, Tim spent 9 years as CFO at Molecular Devices where he helped drive revenue from $38M to $185M through internal growth and acquisitions before selling it for over $600M. In his early career as a healthcare investment banker, Tim helped raise over $1B for life science companies in the public equity markets. He’s currently Chairman of the Analytical, Life Sciences and Diagnostic Tools Association (ALDA), and has an M.B.A. from Stanford and a B.B.A from the University of Wisconsin. Tim is married with 3 children, is out hacking around on the links or riding his bike whenever he can, and happily gets up at the crack of dawn to coach his son’s hockey, lacrosse and baseball teams.

READ BIO

Jack Nielsen

Partner, Novo Ventures
Jack Nielsen, Partner, Novo Ventures

Jack joined Novo A/S in 2001. He is chairman of the Board of Directors of Alios BioPharma Inc., and a member of the Board of Directors of Akebia Therapeutics Inc., Anokion SA, Apollo Endosurgery Inc., and Reata Pharmaceuticals Inc. Previously, he was a board member of MediQuest Therapeutics Inc., NeoMend Inc., Protein Forest Inc., ProteinSimple and Tobira Therapeutics Inc.

From 2006-2012, Jack was employed with Novo Ventures (US) Inc. in San Francisco, California as a partner. From 1990-2001, he held various positions in the Novo Nordisk business area which in 2000 became Novozymes A/S. Before joining Novo A/S, Jack spent several years deeply involved in design-ing the R&D strategy for Novozymes’ activities in the cereal food area, resulting in the development and launch of novel recombinant lipase and amylase enzymes. He has also held positions in marketing and technical services in the textile and personal care area, and started his career in the field of large-scale manufacturing of enzymes.

READ BIO

Brent Ahrens

General Partner, TMIVCITW, Caanan Partners
Brent Ahrens, General Partner, TMIVCITW, Caanan Partners

His term sheets make the NY Times best seller list. His patents file themselves. Other venture capital-ists go through his trash can looking for business plans. He is…The Most Interesting Venture Capitalist in the World.

Brent Ahrens joined Canaan in 1999 as a member of the Kauffman Fellows Program. A raconteur ex-traordinaire, in his work hours, Brent focuses on healthcare investments and has led investments in life sciences companies such as DexCom (DXCM), Revivant (acquired by ZOLL), Peninsula Pharmaceuti-cals (acquired by JNJ), Cerexa (acquired by FRX), Calixa (acquired by CBST), Durata Therapeutics (DRTX), and Elevation Pharmaceuticals (acquired by DNPUF).

Brent serves on the board of Durata Therapeutics, a biopharmaceutical company pursuing late-stage clinical development of novel antibiotic programs. He is also on the boards of EndoGastric Solutions, the leading company offering medical devices for treatment of reflux disease; Minimally Invasive De-vices, a developer of a franchise of products that substantially improve visualization during laparoscop-ic surgery; Relievant MedSystems, a maker of minimally invasive devices to relieve chronic back pain; Semnur, a developer of pain managements solutions; and Spinifex, a biotech company developing new treatments for chronic pain.

Prior to joining Canaan, Brent worked in both commercial and technical roles at General Surgical Inno-vations, Ethicon Endo-Surgery (J&J), and IAP Research. He also has several surgical instrument patents to his credit.

Brent earned an MBA from the Tuck School of Business at Dartmouth College after graduating with a B.S. and M.S. in Mechanical Engineering from the University of Dayton.

READ BIO

Heather Preston, MD

Partner and Managing Director, TPG Biotech
Heather Preston, MD, Partner and Managing Director, TPG Biotech

Prior to joining TPG Biotech in May 2005, Dr. Preston spent two years at JP Morgan Partners where she focused on medical device and biotechnology venture capital investing. Prior to JP Morgan Partners, Dr. Preston was an Entrepreneur-in-Residence with New Enterprise Associates. She also spent five years at McKinsey & Co. in New York, where she was a leader of their pharmaceutical and medical products consulting practice. She advised large pharmaceutical companies and biotechnology compa-nies on critical strategic issues such as R&D portfolio prioritization, M&A opportunities, new technology acquisitions, new product launches and product growth strategies. Dr. Preston has an undergraduate degree in biochemistry from the University of London and a medical degree from the University of Oxford. Dr. Preston completed a post-doctoral fellowship in molecular biology at the Dana Farber Can-cer Institute, Harvard University and trained in Internal Medicine at the Massachusetts General Hospi-tal and subspecialized in Gastroenterology and Hepatology at UCSF. During her academic medical ca-reer, she was the recipient of a Fulbright Scholarship, a Fulbright Cancer Research Scholarship, a Har-lech Scholarship and a Science and Engineering Research Council Post-doctoral Fellowship Award.

Dr. Preston co-founded Virobay Inc., a biotechnology company which is seeking to develop new ther-apies for the treatment of pain and auto-immune diseases. Dr. Preston currently serves on the board of directors of Albireo, Inc.; Alder BioPharmaceuticals, Inc. [ALDR]; Otonomy, Inc. [OTIC]; and Virobay, Inc. She previously served on the boards of Aptalis Pharma (acquired by Forest Labs in February 2014), Conventus, Vibrynt, VLST and Elevation Pharmaceuticals (acquired by Sunovion in September 2012) and is responsible for overseeing TPG Biotech’s investment in Par Pharmaceuticals.

READ BIO

Joseph D. Keegan, Ph.D.

Joseph D. Keegan, Ph.D.

Dr. Keegan has more than 30 years of experience in life science businesses. Most recently as CEO at ForteBio, Inc. he led the Series C financing which raised $25M, established product development and sales strategies that resulted in 2007-11 compounded annual revenue growth of 45%, and exited the company through its sale to Pall Corporation returning $160M to investors. During his 9 year tenure at Molecular Devices Corporation, Dr. Keegan grew the company’s revenues from $30M to $185M through internal growth and acquisitions. In 2007, he oversaw its acquisition by MDS Corporation for $615M. Dr. Keegan joined MDC from Becton Dickinson and Company where he served as President of Worldwide Tissue Culture and Vice President, General Manager of Worldwide Flow Cytometry. Prior to Becton Dickinson, Dr. Keegan was Vice President of the Microscopy and Scientific Instruments Divi-sion of Leica, Inc. He currently serves on the Boards of Directors of Advanced Cellular Diagnostics, Labcyte Corporation as Chairman, Optofluidics, Inc., Response Biomedical Corporation (RBM:Toronto), Seahorse Bioscience Inc., Stereotaxis, Inc. (Nasdaq: STXS), Wasatch Microfluidics, Inc., ALDA as past Chairman and the San Francisco Opera. Dr. Keegan holds a B.A. in Chemistry from Boston University and a Ph.D. in Physical Chemistry from Stanford University.

investors

jobs

Marketing Applications Scientist
 

Build something big with us!

Send Resume

fUNchained team facts

Favorite Unchained

Night Owl or Early Bird

Star Trek or Star Wars

Downton or Walking Dead

get in touch

 

Unchained Labs Boston
10E Commerce Way
Norton, MA 02766
(925) 587-9800

Unchained Labs HQ
6940 Koll Center Parkway, Suite 200
Pleasanton, CA 94566
(925) 587-9800
(800) 815-6384 (North America)

Unchained Labs Shanghai
Room 507, Building 1, Lane 2277 Zuchongzhi Rd
Pudong, Shanghai 201203, China
+86-21-33780983
+86-21-33781083

Unchained Labs London
60 Cressex Enterprise Centre, Lincoln Road
High Wycombe, HP12 3RL, UK
+44 (0)1494 614 659

Service and Support
(925) 587-9800
support@unchainedlabs.com

…they'll never take our FREEDOM!

- WILLIAM WALLACE, BRAVEHEART